Slingshot members are tracking this event:

Allergan Announces FDA Approval of Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
- Label now includes Phase 3 clinical data evaluating the safety and efficacy of AVYCAZ (in combination with metronidazole) in patients with complicated intra-abdominal infections (cIAI) -
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 23, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Avycaz, Snda, Ceftazidime, Avibactam, Beta-lactamases, Esbls, Metronidazole